These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Berdoukas V; Bohane T; Eagle C; Lindeman R; DeSilva K; Tobias V; Painter D; Fraser I Transfus Sci; 2000 Dec; 23(3):239-40. PubMed ID: 11099900 [No Abstract] [Full Text] [Related]
8. Future of oral iron chelator deferiprone. (L1) ICOC committee. Kontoghiorghes GJ; Agarwal MB; Tondury P; Kersten MJ; Jaeger M; Vreugdenhil G; Vania A; Rahman YE Lancet; 1993 Jun; 341(8858):1479-80. PubMed ID: 8099176 [No Abstract] [Full Text] [Related]
9. Effect of oral iron chelator L1 on iron absorption in man. Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Vreugdenhil G; Swaak AJ; Kontoghiorghes GJ; van Eijk HG Lancet; 1989 Dec; 2(8676):1398-9. PubMed ID: 2574342 [No Abstract] [Full Text] [Related]
11. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption. Mehdizadeh M; Nowroozzadeh MH Clin Exp Optom; 2009 Jul; 92(4):392-4. PubMed ID: 19515094 [No Abstract] [Full Text] [Related]
12. Deferiprone: second-line treatment of iron overload in the absence of a better alternative. Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834 [TBL] [Abstract][Full Text] [Related]